ArticleFrontiers in immunology2025
Pan-cancer multi-omics analysis of CCT4 in tumor progression and cancer immunity, with focus on lung adenocarcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Efficient proteostasis and immune evasion are both critical for tumor progression. The chaperonin TRiC/CCT complex, which mediates the folding of cytoskeletal and signaling proteins, has been associated with oncogenesis; however, the specific role of its subunit CCT4 in tumor-immune interactions remain unclear. Methods: To address this gap, we integrated transcriptomics, proteomics, genomics, epigenetics and immunogenomics data. A comprehensive pan-cancer analysis was conducted (including the expression patterns, clinical relevance, prognosis value, immune infiltration of pan-cancer). Then an in-depth analysis of lung adenocarcinoma (LUAD) was carried out through enrichment analysis and single-cell RNA sequencing, and verified through Results: CCT4 was found to be aberrantly upregulated across a majority of tumor types, particularly in LUAD, where elevated expression was associated with advanced stage and inferior survival outcomes. High CCT4 levels were linked to reduced immune cell infiltration and diminished anti-tumor immune signaling, specifically manifested as increased Th2 cell infiltration and decreased Th1 and CD8 Conclusions: CCT4 links enhanced proteostasis with immune evasion in LUAD, acting partly through TRiC complex activity and possibly through independent nuclear functions. These findings refine the understanding of how proteostatic machinery contributes to immune modulation in cancer and highlight CCT4 as a potential molecular node bridging tumor growth and immune suppression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.